Compounded semaglutide is gone. Here's what patients should know.
The FDA's semaglutide shortage-resolved declaration ended 503A and 503B compounding discretion in 2025. A year later, the clinical consequences are landing.
Roughly 300,000 US patients on compounded semaglutide found their prescriptions cut off by mid-2025. The FDA declared the semaglutide shortage resolved on February 21, 2025, triggering a statutory 60-day window for Section 503A compounding pharmacies and a 90-day window for 503B outsourcing facilities to stop preparing compounded semaglutide for patients. Those windows closed April 22 and May 22, 2025, respectively.
A year out, the transition data is mixed. Novo Nordisk's NovoCare direct-to-patient program (launched 2025) brought list cash-pay cost for Wegovy down to $499/month for uninsured patients, filling part of the gap. Telehealth providers — Hims, Ro, Henry Meds, and others — have migrated to branded Wegovy prescriptions where patients qualify. But a significant fraction of the compounded-semaglutide cohort has simply discontinued, with expected weight regain.
Who lost access
Three overlapping groups bore the brunt: commercially insured patients whose plans cover Ozempic (T2D) but not Wegovy (obesity); Medicare and Medicaid patients, since both systems broadly exclude obesity drugs; and cash-pay patients priced out at the ~$1,349/month Wegovy list. NovoCare's $499 option applies only to uninsured patients, leaving under-insured patients in a pricing gap.
What patients should ask
First: does insurance cover Wegovy for obesity (not just Ozempic for T2D)? Coverage has improved at the margin over the past year as employers add obesity benefits, but plans with no obesity coverage remain the majority. Second: if uninsured, does NovoCare's direct-to-patient program apply? Eligibility screening is on novocare.com. Third: does Zepbound (tirzepatide) coverage look different than Wegovy coverage on your plan? In our experience, Lilly's formulary wins differ from Novo's, and one of the two is typically more accessible for any given patient.
What we don't recommend
Buying from research-peptide vendors selling 'semaglutide' for human use. The FDA has explicitly rejected 'research use only' labeling when paired with dosing information or therapeutic claims, and warning letters in late 2024 (Summit Research Peptides, Prime Peptides, Xcel, SwissChems) signaled the direction of enforcement. The price is lower; the regulatory, quality, and legal exposure is not worth it.
Sources